Core Viewpoint - The company has completed the domestic production drug filing for Apsaglar (甲磺酸雷沙吉兰片) to address the aging population trend, enhancing product usability and readability through larger print and electronic instructions [1] Group 1 - The company has received approval from the National Medical Products Administration for the domestic production of Apsaglar [1] - The initiative aims to improve the readability and usability of product information for elderly consumers [1] - The company is among the first batch of pilot enterprises in Chongqing and the third batch nationally for aging-friendly reforms, reflecting its commitment to social responsibility [1] Group 2 - This move is expected to enhance the company's market competitiveness and open new market opportunities [1] - The company aims to better promote its products and meet market demand through these innovations [1]

Core Viewpoint - The company has completed the domestic production registration of Apsaglarin tablets, which is a response to the aging population trend and aims to enhance the readability and usability of product information [1] Group 1: Product Registration and Compliance - The company has received approval from the National Medical Products Administration for the domestic production registration of Apsaglarin tablets [1] - The registration includes an application for an age-friendly product information leaflet, which features larger font sizes and the introduction of an electronic version [1] Group 2: Social Responsibility and Innovation - The company is among the first batch of pilot enterprises in Chongqing and the third batch nationally for age-friendly reform, reflecting its commitment to social responsibility [1] - This initiative demonstrates the company's efforts in product and service innovation aimed at the elderly population [1] Group 3: Market Opportunities - The completion of the registration is expected to enhance the company's market competitiveness and open new market opportunities [1] - The company aims to better promote its products and meet market demand through this initiative [1]

证券代码：002907 证券简称：华森制药 公告编号：2025-086 重庆华森制药股份有限公司 药 品 通 用 名 称：甲磺酸雷沙吉兰片 备 案 号：渝备 2025047469 关于公司产品完成境内生产药品备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日从国家药品监督管 理局（以下简称"国家药监局"）网站查询获知公司产品甲磺酸雷沙吉兰片完成 境内生产药品备案（药品说明书适老化申请），并于国家药监局网站公示备案信 息。现将相关情况公告如下： 一、药品基本信息 （一）药品说明书适老化申请 1.甲磺酸雷沙吉兰片 药 品 批 准 文 号 / 原 料 药 登 记 号 ：国药准字 H20243081 上 市 许 可 持 有 人：重庆华森制药股份有限公司 上市许可持有人地址：重庆市荣昌区工业园区 二、药品其他相关情况 甲磺酸雷沙吉兰片为国家医保乙类药，是公司自主研发的仿制药，公司是国 内第四家仿制药获批厂家，该药品质量和疗效等同原研产品。此外，公司自产该 品种原料药，为原料药制剂一体化品种，详见公司于 2024 ...

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has announced that its product, Apsaglar (Apsaglar tablets), has completed the domestic production drug filing and the application for the aging-friendly drug label, which has been publicly disclosed on the National Medical Products Administration (NMPA) website [1] Group 1 - The product Apsaglar has received approval for domestic production drug filing [1] - The application for aging-friendly drug labeling has been successfully submitted [1] - The filing information has been officially published on the NMPA website [1]

Group 1 - The company Huason Pharmaceutical (002907.SZ) has announced that its product, Apsa-Rasagiline Tablets, has completed the domestic production drug filing with the National Medical Products Administration (NMPA) [1] - The filing includes an application for the drug's instructions to be adapted for elderly patients, which indicates a focus on improving accessibility for this demographic [1] - The registration information has been publicly disclosed on the NMPA's website, enhancing transparency regarding the company's product status [1]

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has completed the domestic production registration of its product, Amlodipine Besylate Tablets, which includes an elderly-friendly drug instruction manual. This registration aims to enhance readability and usability, addressing the aging population trend, and is expected to improve market competitiveness and open new market opportunities, although it will not have a significant short-term impact on the company's performance [1]. Group 1 - The product Amlodipine Besylate Tablets is classified as a Category B drug under the national medical insurance system [1]. - The drug is indicated for the treatment of primary Parkinson's disease, both as a standalone treatment and as an adjunct to Levodopa [1]. - The registration includes both a simplified paper version and a complete electronic version of the drug instruction manual [1]. Group 2 - The registration is part of the company's strategy to respond to the aging population trend [1]. - The expected outcome of this registration is to enhance the product's market competitiveness [1]. - The company anticipates that this move will help in exploring new market opportunities [1].

Core Viewpoint - Chongqing Huason Pharmaceutical Co., Ltd. has received a change in its drug production license, extending the contract manufacturing period for Montelukast Sodium Granules until March 2, 2026, which is expected to enhance the company's production capacity utilization [1][3]. Group 1: License Change Details - The change involves the extension of the contract manufacturing period for Montelukast Sodium Granules, a product commissioned by Youhua Pharmaceutical Technology Co., Ltd. [1]. - The new drug production license number is 渝20150018, issued by the Chongqing Drug Administration [1]. Group 2: Product Information - Montelukast Sodium Granules are indicated for the prevention and long-term treatment of asthma in children over one year old, as well as for alleviating symptoms of allergic rhinitis in children aged 2 to 5 [2]. - The product is classified as a national medical insurance category B product and is recommended in several authoritative clinical guidelines, highlighting its significant market presence and advantages in pediatric formulations [2]. Group 3: Market Performance - The overall market for Montelukast Sodium has reached maturity, but the granule formulation for children continues to show strong growth potential [2]. - In the past five years (2020-2024), the cumulative sales of Montelukast Sodium formulations in domestic hospital terminals have reached 5.545 billion yuan [2]. Group 4: Impact on the Company - The change in the drug production license is expected to improve the company's production capacity utilization, although it will not have a significant short-term impact on the company's performance [3].

证券代码：002907 证券简称：华森制药 公告编号：2025-085 重庆华森制药股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监督 管理局颁发的《药品生产许可证》（许可证编号：渝 20150018），本次变更主要 涉及延续受托有效期。具体情况如下： 一、变更内容 1.延续受托有效期：接受佑华医药科技有限公司委托生产孟鲁司特钠颗粒（国 药准字 H20234652），受托有效期延长至 2026 年 03 月 02 日。 二、变更后的《药品生产许可证》具体内容 重庆市荣昌区昌州街道板桥路 143 号：粉针剂，冻干粉 针剂，片剂（含抗肿瘤类），硬胶囊剂（含抗肿瘤类， 克唑替尼胶囊（仅供注册申报用）），软胶囊剂，颗粒 剂，散剂，中药前处理及提取，中药饮片，滴剂（胶囊 剂）*** 三、产品情况说明 适应症：①适用于 1 岁以上儿童哮喘的预防和长期治疗，包括预防白天和夜间 的哮喘症状，治疗对阿司匹林敏感的哮喘患者以及预防运动诱发的支气管收缩；② 适用于减轻过 ...

| 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | 2025-11-14 | 002907 | 华森制药 | 15.28 | 13.10 | 200.17 机构专用 | | 华泰证券股份有限 | | | | | | | | | 公司宜都长江大道 | | | | | | | | | 证券营业部 | 11月14日，华森制药大宗交易成交13.1万股，成交额200.17万元，占当日总成交额的1%，成交价15.28 元，较市场收盘价17.34元折价11.88%。 ...

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]